| Management target | Revenue 18.0% FY32 |
|---|
| Revenue growth | 20% YoY growth to ₹946 Cr driven by animal health formulations. |
|---|---|
| Margins | EBITDA margins expanded 540 bps YoY to 21.6% via integration. |
| Order book | API orders rebounding after June lull caused by market volatility. |
| Demand visibility | Strong visibility in companion animal and human oncology API markets. |
| Management confidence | Highly confident, emphasizing consistent results and a strengthened debt-free balance sheet. |
Growth
Revenue grew 19.5% YoY to ₹946 Cr; EBITDA increased 59.2% led by operational efficiency and backward integration.
Outlook
Targeting $1 billion revenue by FY32 with 18% CAGR; focused on companion animal and complex oncology APIs.
Risks
Near-term API pricing volatility and raw material cost fluctuations impacted sequential growth in the API segment.
Last quarter's promises, checked
Delivered
- Guided 13% p.a. revenue growth → delivered 20% (= BEAT)
- Guided 60% p.a. EBITDA growth → delivered 59.2% (= BEAT)
- Guided FY26 revenue ₹34,203 MN → delivered ₹37,840 MN annualized (= BEAT)
Partly delivered
- Guided EBITDA margin expansion → delivered 21.6% but API segment volatility persists (= PARTIAL)
Earnings Call Transcript filed with NSE, NSE: VIYASH. Summary written with AI assistance from the document.
Viyash Scientific Ltd: key numbers
- Share price
- ₹244.35
- Market cap
- ₹10,791 Cr
- Revenue (annual)
- ₹3,420 Cr
- Net profit (annual)
- ₹177.3 Cr
- P/E (TTM)
- 63.0×Sector 50.4×
- Promoter holding
- 61.31%+0.00% QoQ
- FII holding
- 4.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Viyash Scientific Ltd
All →Viyash Scientific Employee Stock Options
Viyash Scientific allotted 1,107,309 ESOP shares at exercise prices of ₹86 and ₹101. Paid-up capital rose to ₹88.33 Crore post-allotment.
Viyash Scientific Merger & Restructuring
Viyash Scientific Limited announced receipt of Italian regulatory approval for its subsidiary Alivira Animal Health's acquisition of BioForLife Italia S.r.l. The transaction completion timeline is extended.
Viyash Scientific Acquisition
Viyash Scientific Limited received Italian regulatory approval for its proposed 100% acquisition of BioForLife Italia S.r.l., with the completion timeline now extended by two months.
Viyash Scientific Employee Stock Options
Viyash Scientific Limited allotted 6,12,773 equity shares following the exercise of options under its ESOP 2020 and 2026 schemes. The company's paid-up capital increased to Rs. 88.10 Crore.
Viyash Scientific Investor Presentation: Key Takeaways
Viyash Scientific delivered strong Q1 FY27 results with 19.5% revenue growth and significant margin expansion. Integration is complete, and the company is now virtually debt-free, pivoting toward oncology and companion animal health.
- Call
- Guides 18% growth
Viyash Scientific Investor Presentation: Key Takeaways
Viyash Scientific reported strong Q1 FY27 results with 19.5% YoY revenue growth and 59.2% EBITDA growth, driven by integration success and operational leverage.